Stockscreener 앱 받기
4.65
2.52%
-0.12
시간 외 거래:
4.65
전일 마감가:
$4.77
열려 있는:
$4.94
하루 거래량:
124.12K
Relative Volume:
1.45
시가총액:
$77.35M
수익:
-
순이익/손실:
$-23.87M
주가수익비율:
-0.2364
EPS:
-19.67
순현금흐름:
$-47.63M
1주 성능:
+7.14%
1개월 성능:
+16.83%
6개월 성능:
+35.57%
1년 성능:
+55.52%
1일 변동 폭
$4.65
$4.97
1주일 범위
$4.30
$4.97
52주 변동 폭
$2.30
$4.97
폴리피드 Stock (PYPD) Company Profile
PYPD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.65 | 79.35M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
Why analysts remain bullish on PolyPid Ltd. stockNew Guidance & Stock Market Timing Techniques - ulpravda.ru
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Why PolyPid Ltd. stock could see breakout soonQuarterly Trade Review & Comprehensive Market Scan Insights - Улправда
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Polypid names medtech veteran Brooke Story as board chairman - marketscreener.com
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
PolyPid (PYPD) appoints medtech veteran Brooke Story as board chairman - Stock Titan
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets
Transcript : PolyPid Ltd.Special Call - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD) - TradingView — Track All Markets
PolyPid receives FDA support for D-PLEX100 NDA submission By Investing.com - Investing.com Australia
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA - FinancialContent
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com Nigeria
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 By Investing.com - Investing.com South Africa
PolyPid receives FDA support for D-PLEX100 NDA submission - Investing.com
PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission - marketscreener.com
Polypid announces positive FDA Pre-NDA meeting minutes - marketscreener.com
PolyPid Gains FDA Support for D-PLEX100 NDA Submission - TipRanks
PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission - TipRanks
PolyPid (NASDAQ: PYPD) highlights positive FDA pre-NDA minutes for D-PLEX100 NDA path - Stock Titan
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
How institutional buying supports PolyPid Ltd. stockExit Point & Expert Approved Momentum Ideas - Newser
PolyPid stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
PolyPid stock rating reiterated at Market Outperform by Citizens By Investing.com - Investing.com India
PolyPid Expands Share Offering to Strengthen Financial Position - The Globe and Mail
PYPD ups at-the-market ordinary share program limit to $15M - Stock Titan
PolyPid (PYPD) raises ordinary share Sales Agreement capacity - Stock Titan
PolyPid Ltd. to Host Virtual KOL Event on D-PLEX100 and Surgical Site Infection Prevention - Quiver Quantitative
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 - Sahm
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):